Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Mar 10  •  04:00PM ET
1.76
Dollar change
+0.16
Percentage change
10.00
%
Index- P/E- EPS (ttm)-2.36 Insider Own29.94% Shs Outstand37.62M Perf Week16.56%
Market Cap66.21M Forward P/E- EPS next Y-2.00 Insider Trans-0.15% Shs Float26.36M Perf Month14.29%
Enterprise Value-53.93M PEG- EPS next Q-0.53 Inst Own18.82% Short Float7.52% Perf Quarter-1.12%
Income-87.87M P/S2.63 EPS this Y11.47% Inst Trans4.60% Short Ratio7.01 Perf Half Y-5.38%
Sales25.21M P/B0.42 EPS next Y4.27% ROA-31.50% Short Interest1.98M Perf YTD8.64%
Book/sh4.22 P/C0.41 EPS next 5Y6.93% ROE-44.67% 52W High3.95 -55.44% Perf Year-14.15%
Cash/sh4.27 P/FCF- EPS past 3/5Y-26.57% -42.49% ROIC-45.47% 52W Low1.23 43.09% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y13.59% 219.15% Gross Margin78.91% Volatility11.12% 7.21% Perf 5Y-
Dividend TTM- EV/Sales-2.14 EPS Y/Y TTM9.77% Oper. Margin-380.85% ATR (14)0.12 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.22 Sales Y/Y TTM-51.79% Profit Margin-348.54% RSI (14)61.94 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio7.22 EPS Q/Q4.24% SMA2015.11% Beta0.34 Target Price9.50
Payout- Debt/Eq0.26 Sales Q/Q-59.32% SMA5010.21% Rel Volume2.77 Prev Close1.60
Employees119 LT Debt/Eq0.22 EarningsMar 05 AMC SMA200-8.06% Avg Volume282.94K Price1.76
IPOFeb 09, 2024 Option/ShortNo / Yes EPS/Sales Surpr.2.62% -46.64% Trades Volume782,943 Change10.00%
Date Action Analyst Rating Change Price Target Change
May-07-24Initiated H.C. Wainwright Buy $10
May-02-24Downgrade JP Morgan Overweight → Neutral $16 → $6
Mar-05-24Initiated Wells Fargo Overweight $25
Mar-05-24Initiated TD Cowen Outperform
Mar-05-24Initiated JP Morgan Overweight $16
Mar-05-24Initiated Jefferies Buy $23
Mar-05-24Initiated Chardan Capital Markets Buy $21
Mar-05-24Initiated BMO Capital Markets Outperform $22
Mar-05-26 05:30PM
04:28PM
04:05PM
Feb-26-26 05:30PM
Feb-23-26 04:05PM
08:30AM Loading…
Jan-12-26 08:30AM
Dec-02-25 12:32PM
Dec-01-25 07:00AM
Nov-17-25 08:00AM
Nov-12-25 05:20AM
Nov-11-25 05:10PM
04:09PM
04:02PM
04:01PM
Nov-10-25 05:45PM
08:50AM Loading…
Nov-06-25 08:50AM
Nov-05-25 05:35PM
Oct-22-25 10:02AM
Oct-20-25 12:00PM
Aug-12-25 05:40PM
05:25PM
04:37PM
04:05PM
Aug-11-25 04:05PM
Aug-07-25 08:35AM
Jul-29-25 10:23AM
Jul-18-25 10:06AM
09:41AM
Jul-14-25 11:12AM
May-14-25 06:00AM
05:40PM Loading…
May-13-25 05:40PM
04:42PM
04:30PM
May-08-25 09:30AM
May-06-25 07:15AM
May-02-25 07:00AM
Apr-01-25 11:50AM
Mar-17-25 04:05PM
Mar-13-25 06:19AM
Feb-11-25 08:55AM
Jan-28-25 08:00AM
Jan-22-25 11:54AM
Jan-16-25 08:55AM
Jan-15-25 08:55AM
Jan-08-25 04:05PM
Dec-11-24 06:30PM
Dec-09-24 09:16PM
Dec-08-24 06:05AM
Nov-18-24 12:00PM
Nov-13-24 04:37PM
04:05PM
Nov-05-24 04:05PM
Oct-29-24 05:45AM
Oct-24-24 08:04AM
Oct-23-24 05:45AM
Oct-14-24 08:58PM
Oct-01-24 03:14PM
Sep-19-24 07:15PM
Sep-03-24 04:05PM
Aug-29-24 07:32PM
Aug-28-24 06:10PM
Aug-26-24 09:00PM
Aug-14-24 08:11AM
08:05AM
Aug-12-24 06:29PM
Aug-05-24 09:00PM
Jun-03-24 04:30PM
04:17PM
May-29-24 04:00PM
May-14-24 10:54PM
04:05PM
May-04-24 10:49AM
May-02-24 06:04AM
May-01-24 04:00PM
01:53PM
Apr-08-24 08:00AM
Mar-27-24 09:16AM
Feb-29-24 04:30PM
Feb-13-24 04:35PM
Feb-08-24 10:16PM
Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wapnick PamelaChief Financial OfficerMar 05 '26Sale1.601,5812,530187,375Mar 09 05:16 PM
Wein MatthewSee RemarksMar 05 '26Sale1.60482771114,549Mar 09 05:16 PM
Irish JianChief Executive OfficerMar 05 '26Sale1.601,6072,571333,770Mar 09 05:15 PM
Thomas Brian C.DirectorDec 05 '25Sale1.773,8306,7862,510,960Dec 08 01:56 PM
Wein MatthewSee RemarksDec 05 '25Sale1.77199353115,031Dec 08 01:51 PM
Wapnick PamelaChief Financial OfficerDec 05 '25Sale1.771,5762,793188,956Dec 08 01:49 PM
Irish JianChief Executive OfficerDec 05 '25Sale1.771,6022,839563,839Dec 08 01:38 PM
Thomas Brian C.DirectorSep 05 '25Sale1.812,7014,8892,514,790Dec 01 07:34 PM
Wapnick PamelaChief Financial OfficerSep 05 '25Sale1.811,5762,85370,532Dec 01 07:32 PM
Irish JianChief Executive OfficerSep 05 '25Sale1.811,6022,900316,941Dec 01 07:28 PM
Wein MatthewSee RemarksSep 05 '25Sale1.8119936019,230Dec 01 06:37 PM
Noonberg Sarah B.FORMER OFFICERSep 11 '25Proposed Sale1.9035,83268,081Sep 11 04:25 PM
Sebastian BernalesAffiliateJul 09 '25Proposed Sale1.91769,8451,470,404Jul 09 06:34 PM
Wein MatthewSee RemarksJun 06 '25Sale1.7519934816,693Jun 09 07:04 PM
Noonberg Sarah B.Chief Medical OfficerJun 06 '25Sale1.755,2399,168109,135Jun 09 06:57 PM
Wapnick PamelaChief Financial OfficerJun 06 '25Sale1.751,5762,75872,108Jun 09 06:54 PM
Thomas Brian C.Chief Executive OfficerJun 06 '25Sale1.7510,78518,8742,517,491Jun 09 06:50 PM
Irish JianSee RemarksJun 06 '25Sale1.756,39011,182315,543Jun 09 06:20 PM